Susquehanna International Group
IKT icon

Susquehanna International Group’s Inhibikase Therapeutics IKT Stock Holding History

Susquehanna International Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59K Buy
35,100
+13,568
+63% +$24.1K ﹤0.01% 12592
2025
Q4 		$44.1K Sell
21,532
-24,073
-53% -$38.3K ﹤0.01% 11790
2025
Q3 		$73.9K Sell
45,605
-337,466
-88% -$585K ﹤0.01% 11719
2025
Q2 		$747K Sell
383,071
-121,554
-24% -$238K ﹤0.01% 8193
2025
Q1 		$1.11M Buy
+504,625
New +$1.27M ﹤0.01% 6993
2024
Q2 		– Sell
-22,616
Closed -$48.9K – 12594
2024
Q1 		$48.9K Buy
+22,616
New +$49.9K ﹤0.01% 11572
2023
Q1 		– Sell
-5,109
Closed -$15.3K – 13001
2022
Q4 		$15.3K Buy
+5,109
New +$20.3K ﹤0.01% 11844
2022
Q2 		– Sell
-2,126
Closed -$19K – 13370
2022
Q1 		$19K Buy
+2,126
New +$17.1K ﹤0.01% 12634

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's IKT Position: Q1 2026 in Review

Susquehanna International Group increased its Inhibikase Therapeutics (IKT) stake by 63% in Q1 2026, buying an estimated $24.1K and bringing the position to 35,100 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #12592.

Susquehanna International Group first reported a position in IKT in Q1 2022 and has held it in 8 quarters since. The position peaked at $1.11M in Q1 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Susquehanna International Group held 35,100 shares of Inhibikase Therapeutics worth $59K as of Q1 2026.
  • Susquehanna International Group bought 13,568 Inhibikase Therapeutics shares in Q1 2026, an estimated $24.1K.
  • Inhibikase Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12592 holding.
  • Susquehanna International Group first reported a position in Inhibikase Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Susquehanna International Group's Inhibikase Therapeutics position peaked at $1.11M in Q1 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.